Sana Biotechnology, Inc.

Sana Biotechnology, Inc. is a biotechnology company focused on engineering cells as medicines to treat diseases with unmet medical needs. The company develops both ex vivo and in vivo cell engineering platforms. Its pipeline includes UP421, a hypoimmune-modified (HIP) allogeneic primary islet cell product in phase 1 clinical trials for type 1 diabetes; SC451, a HIP-modified stem cell-derived pancreatic islet cell therapy in preclinical trials for type 1 diabetes; and SG293 and SG299, CD8-targeted fusosomes for B cell hematologic malignancies and B cell mediated autoimmune diseases. Sana also has licensing agreements with Beam Therapeutics for CRISPR Cas12b nuclease editing technology and with Harvard College for hypoimmune-modified cell intellectual property.

Sana Biotechnology, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol SANA. Its shares are traded in US dollars (USD), reflecting its primary listing in the United States. The company's stock is available for trading during regular Nasdaq market hours, and investors can buy and sell shares through brokerage accounts that support US equities.

Sana Biotechnology operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing cell-based therapies that aim to modify or replace cells to treat diseases. The company's work spans areas such as type 1 diabetes, autoimmune diseases, and oncology, leveraging advanced gene editing and cell engineering technologies to create potential new treatment options.

Sana Biotechnology is headquartered in Seattle, Washington, United States. The company primarily serves the US market, as indicated by its regional classification as 'us'. Its research and development activities are based in the US, and it collaborates with institutions like Mayo Clinic for developing SC451, a pancreatic islet cell therapy for type 1 diabetes. While its focus is on the US, the company's therapies, if approved, could potentially address global unmet medical needs in diabetes, autoimmune diseases, and oncology.

Sana Biotechnology's pipeline includes several key product candidates. UP421 is a HIP-modified allogeneic primary islet cell product in phase 1 clinical trials for type 1 diabetes. SC451 is a HIP-modified, stem cell-derived pancreatic islet cell therapy in preclinical development for type 1 diabetes, developed in collaboration with Mayo Clinic. For oncology and autoimmune diseases, the company has SG293 and SG299, which are CD8-targeted fusosomes designed to treat B cell hematologic malignancies and B cell mediated autoimmune diseases. Additionally, Sana has licensing agreements with Beam Therapeutics for CRISPR Cas12b nuclease editing technology and with Harvard College for hypoimmune-modified cell intellectual property to support its cell engineering platforms.